Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-athero: DPP-4 vs SGLT2 Inhibitors in T2DM
NCT02528019Phase 4Unknown
- Sponsor
- Kurume University
- Start
- Aug 2015
- Primary completion
- Aug 2017
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Kurume University. Primary endpoint: Change in arterial stiffness from baseline as measured by cardio-ankle vascular index (CAVI) at 6 months. Status: unknown.
02
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02528019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02528019.